TrialBreast cancer (Tokyo, Japan)2025

Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2- advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis.

Masato Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.